CYP3A5 gene variation influences cyclosporine a metabolite formation and renal cyclosporine disposition

Transplantation

Volumn 95, Issue 6, 2013, Pages 821-827

  Zheng, Songmao ^a   Tasnif, Yasar ^a   Hebert, Mary F ^a   Davis, Connie L ^a   Shitara, Yoshihisa ^a   Calamia, Justina C ^a   Lin, Yvonne S ^a   Shen, Danny D ^a   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Chronic calcineurin inhibitor nephrotoxicity; Cyclosporine A; CYP3A5 genotype; Intrarenal metabolism; Secondary metabolites

Indexed keywords

CYCLOSPORIN A; CYCLOSPORINE A METABOLITE AM1; CYCLOSPORINE A METABOLITE AM19; CYCLOSPORINE A METABOLITE AM1C; CYCLOSPORINE A METABOLITE AM1C9; CYCLOSPORINE A METABOLITE AM4N; CYCLOSPORINE A METABOLITE AM9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; AM 19; CYCLOSPORIN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A;

AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; CYP3A5 GENE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VIVO STUDY; KIDNEY METABOLISM; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; URINARY EXCRETION; ADULT; DRUG EFFECT; FEMALE; GENETICS; GLOMERULUS FILTRATION RATE; KIDNEY; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; TIME;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC VARIATION; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MASS SPECTROMETRY; PHARMACOGENETICS; TIME FACTORS;

MLCS; MLOWN;

EID: 84877620041     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31827e6ad9     Document Type: Article

References (41)

1. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2: 1323.
2. Klintmalm GB, Iwatsuki S, Starzl TE. Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet 1981; 1: 470.
3. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699.
4. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
5. Naesens M, Kuypers D, Sarwal MM. The bumpy road of genomic medicine in transplantation: lessons from studies on calcineurin inhibitor nephrotoxicity. Transplantation 2012; 93: 578.
6. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephro-toxicity. Clin J Am Soc Nephrol 2009; 4: 481.
7. Christians U, Sewing KF. Cyclosporin metabolism in transplant patients. Pharmacol Ther 1993; 57: 291.
8. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23: 1315.
9. Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162.
10. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383.
11. Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996; 50: 52.
12. Givens RC, Lin YS, Dowling AL, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003; 95: 1297.
13. Dai Y, Iwanaga K, Lin YS, et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 2004; 68: 1889.
14. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmaco-dynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 2010; 49: 141.
15. Lensmeyer GL, Wiebe DA, Carlson IH. Deposition of nine metabolites of cyclosporine in human tissues, bile, urine, and whole blood. Transplant Proc 1988; 20: 614.
16. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27: 201.
17. Vollenbroeker B, Koch JH, Fobker M, et al. Determination of cyclo-sporine and its metabolites in blood via HPLC-MS and correlation to clinically important parameters. Transplant Proc 2005; 37: 1741.
18. Christians U, Kohlhaw K, Budniak J, et al. Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicity. Eur J Clin Pharmacol 1991; 41: 285.
19. Kempkes-Koch M, Fobker M, Erren M, et al. Cyclosporine A metabolite AM19 as a potential biomarker in urine for CSA nephropathy. Transplant Proc 2001; 33: 2167.
20. Bowers LD. Studies of cyclosporine and metabolite toxicity in renal and hepatocyte culture systems. Transplant Proc 1990; 22: 1135.
21. Copeland KR, Thliveris JA, Yatscoff RW. Toxicity of cyclosporine metabolites. Ther Drug Monit 1990; 12: 525.
22. Copeland KR, Yatscoff RW. Comparison of the effects of cyclosporine and its metabolites on the release of prostacyclin and endothelin from mesangial cells. Transplantation 1992; 53: 640.
23. Zhao Y, Song M, Guan D, et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 2005; 37: 178.
24. Loh PT, Lou HX, Zhao Y, et al. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplant Proc 2008; 40: 1690.
25. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and phar-macokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245.
26. Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422.
27. Min DI, Ellingrod VL, Marsh S, et al. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2004; 26: 524.
28. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147.
29. el-Agroudy AE, Sobh MA, Hamdy AF, et al. A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up. Transplantation 2004; 77: 1371.
30. Omar G, Whiting PH, Hawksworth GM, et al. Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ther Drug Monit 1997; 19: 436.
31. Eng HS, Mohamed Z, Calne R, et al. The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int 2006; 69: 1858.
32. Klauke B, Wirth A, Zittermann A, et al. No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. J Heart Lung Transplant 2008; 27: 741.
33. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501.
34. Kreutz R, Bolbrinker J, van der Sman-de Beer F, et al. CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. Pharmacogenomics J 2008; 8: 416.
35. de Denus S, Zakrzewski M, Barhdadi A, et al. Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. J Heart Lung Transplant 2011; 30: 326.
36. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmaco-dynamics of calcineurin inhibitors: part II. Clin Pharmacokinet 2010; 49: 207.
37. Sirianni GL, Pang KS. Inhibition of esterolysis of enalapril by para-oxon increases the urinary clearance in isolated perfused rat kidney. Drug Metab Dispos 1999; 27: 931.
38. Zheng S, Tasnif Y, Hebert MF, et al. Measurement and compartmen-tal modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin Pharmacol Ther 2012; 92: 737.
39. Hebert MF, Dowling AL, Gierwatowski C, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13: 661.
40. Asano T, Takahashi KA, Fujioka M, et al. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteo-necrosis of the femoral head after kidney transplantation. Pharmaco-genetics 2003; 13: 675.
41. Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther 2008; 84: 248.